These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 33956869)

  • 41. A Cross-Sectional Study Examining the Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in a University Student Population.
    Tilley K; Ayvazyan V; Martinez L; Nanda N; Kawaguchi ES; O'Gorman M; Conti D; Gauderman WJ; Van Orman S
    J Adolesc Health; 2020 Dec; 67(6):763-768. PubMed ID: 33071164
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
    Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
    Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunocompromised Seroprevalence and Course of Illness of SARS-CoV-2 in One Pediatric Quaternary Care Center.
    Freeman MC; Rapsinski GJ; Zilla ML; Wheeler SE
    J Pediatric Infect Dis Soc; 2021 Apr; 10(4):426-431. PubMed ID: 33049042
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence of Severe Acute Respiratory Syndrome Coronavirus-2-specific Antibodies in German Blood Donors during the COVID-19 Pandemic.
    Runkel S; Kowalzik F; Gehring S; Winter J; Grandt CL; Marron M; Seifert-Hitzler S; Hitzler WE
    Clin Lab; 2020 Oct; 66(10):. PubMed ID: 33073955
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020.
    Yoshiyama T; Saito Y; Masuda K; Nakanishi Y; Kido Y; Uchimura K; Mitarai S; Suzuki T; Nakagama Y; Kubota H; Satomi M; Uchikoba S; Ohnishi M; Wakita T; Kato S; Kato K
    Emerg Infect Dis; 2021 Feb; 27(2):628-631. PubMed ID: 33496235
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Seroprevalence of SARS-CoV-2 antibodies in people with an acute loss in their sense of smell and/or taste in a community-based population in London, UK: An observational cohort study.
    Makaronidis J; Mok J; Balogun N; Magee CG; Omar RZ; Carnemolla A; Batterham RL
    PLoS Med; 2020 Oct; 17(10):e1003358. PubMed ID: 33001967
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care Clinic-Based Point-of-Care Antibody Testing.
    Takita M; Matsumura T; Yamamoto K; Yamashita E; Hosoda K; Hamaki T; Kusumi E
    J Prim Care Community Health; 2020; 11():2150132720942695. PubMed ID: 32674696
    [No Abstract]   [Full Text] [Related]  

  • 48. [The prevalence rate of anti-SARS-CoV-2-IgG is 1.2% - Screening in asymptomatic outpatients in Germany (Northrhine-Westfalia)].
    Herrmann BL
    MMW Fortschr Med; 2020 Aug; 162(14):44-46. PubMed ID: 32780376
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign.
    Pan Y; Li X; Yang G; Fan J; Tang Y; Hong X; Guo S; Li J; Yao D; Cheng Z; Yuan Y; Li Y; Wang X
    Clin Microbiol Infect; 2021 Feb; 27(2):253-257. PubMed ID: 33035672
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevalence of IgG antibodies against SARS-CoV-2 among healthcare workers in a tertiary pediatric hospital in Poland.
    Kasztelewicz B; Janiszewska K; Burzyńska J; Szydłowska E; Migdał M; Dzierżanowska-Fangrat K
    PLoS One; 2021; 16(4):e0249550. PubMed ID: 33793673
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High prevalence of anti-SARS-CoV-2 IgG antibody in the Xikrin of Bacajá (Kayapó) indigenous population in the brazilian Amazon.
    Rodrigues EPS; Abreu IN; Lima CNC; da Fonseca DLM; Pereira SFG; Dos Reis LC; Vallinoto IMVC; Guerreiro JF; Vallinoto ACR
    Int J Equity Health; 2021 Jan; 20(1):50. PubMed ID: 33509206
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis.
    Rostami A; Sepidarkish M; Leeflang MMG; Riahi SM; Nourollahpour Shiadeh M; Esfandyari S; Mokdad AH; Hotez PJ; Gasser RB
    Clin Microbiol Infect; 2021 Mar; 27(3):331-340. PubMed ID: 33228974
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analysis of adjunctive serological detection to nucleic acid test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection diagnosis.
    Liu R; Liu X; Yuan L; Han H; Shereen MA; Zhen J; Niu Z; Li D; Liu F; Wu K; Luo Z; Zhu C
    Int Immunopharmacol; 2020 Sep; 86():106746. PubMed ID: 32619956
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study.
    Trieu MC; Bansal A; Madsen A; Zhou F; Sævik M; Vahokoski J; Brokstad KA; Krammer F; Tøndel C; Mohn KGI; Blomberg B; Langeland N; Cox RJ;
    J Infect Dis; 2021 Feb; 223(4):589-599. PubMed ID: 33247924
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Low rate of COVID-19 seroconversion in health-care workers at a Department of Infectious Diseases in Sweden during the later phase of the first wave; a prospective longitudinal seroepidemiological study.
    Rashid-Abdi M; Krifors A; Sälléber A; Eriksson J; Månsson E
    Infect Dis (Lond); 2021 Mar; 53(3):169-175. PubMed ID: 33232190
    [No Abstract]   [Full Text] [Related]  

  • 56. Seroprevalence of antibodies against SARS-Cov-2 in the high impacted sub-district in Jakarta, Indonesia.
    Herlinda O; Bella A; Kusnadi G; Swasthika Nurshadrina D; Thoriq Akbar M; Nida S; Salama N; Ariawan I; Saminarsih D
    PLoS One; 2021; 16(12):e0261931. PubMed ID: 34941968
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevalence of and risk factors for depression, anxiety, and stress in non-hospitalized asymptomatic and mild COVID-19 patients in East Java province, Indonesia.
    Lusida MAP; Salamah S; Jonatan M; Wiyogo IO; Asyari CH; Ali ND; Asmara J; Wahyuningtyas RI; Triyono EA; Ratnadewi NK; Irzaldy A; Alkaff FF
    PLoS One; 2022; 17(7):e0270966. PubMed ID: 35797394
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic.
    Buss LF; Prete CA; Abrahim CMM; Mendrone A; Salomon T; de Almeida-Neto C; França RFO; Belotti MC; Carvalho MPSS; Costa AG; Crispim MAE; Ferreira SC; Fraiji NA; Gurzenda S; Whittaker C; Kamaura LT; Takecian PL; da Silva Peixoto P; Oikawa MK; Nishiya AS; Rocha V; Salles NA; de Souza Santos AA; da Silva MA; Custer B; Parag KV; Barral-Netto M; Kraemer MUG; Pereira RHM; Pybus OG; Busch MP; Castro MC; Dye C; Nascimento VH; Faria NR; Sabino EC
    Science; 2021 Jan; 371(6526):288-292. PubMed ID: 33293339
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A spatial-temporal description of the SARS-CoV-2 infections in Indonesia during the first six months of outbreak.
    Aisyah DN; Mayadewi CA; Diva H; Kozlakidis Z; Siswanto ; Adisasmito W
    PLoS One; 2020; 15(12):e0243703. PubMed ID: 33351801
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Viral shedding and the durability of immunoglobulin G antibodies to severe acute respiratory syndrome coronavirus 2.
    Lusida MI; Gunawan E; Megasari NLA; Yamani LN; Juniastuti ; Utsumi T; Mori Y
    Microbiol Immunol; 2022 Apr; 66(4):173-178. PubMed ID: 35007349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.